Sign In
Buy PRTK
$2.23
+0 (+0%)
At Close: Dec 19, 2023
Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Lags Revenue Estimates
06:48pm, Thursday, 03'rd Nov 2022
Paratek (PRTK) delivered earnings and revenue surprises of -40.74% and 13.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
08:05pm, Tuesday, 01'st Nov 2022 GlobeNewswire Inc.
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sa
Paratek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare Conference
08:00am, Tuesday, 01'st Nov 2022
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi
Paratek Announces First Milestone Towards Creating a U.S. Manufacturing Supply Chain for NUZYRA® (omadacycline) under BARDA Project BioShield Contract
12:00pm, Monday, 31'st Oct 2022 GlobeNewswire Inc.
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announces the commercial availability of U.S.-produced NUZYRA® (omadacycline) tablets. This milestone fo
Paratek Pharmaceuticals to Report Third-Quarter 2022 Financial Results on Nov. 3
08:00am, Tuesday, 25'th Oct 2022
BOSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, Nov. 3 at 4:30 p
Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2022
08:05pm, Thursday, 13'th Oct 2022 GlobeNewswire Inc.
Highlights include data from non-clinical and microbiology programs and real-world patient use
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
08:05pm, Monday, 03'rd Oct 2022 GlobeNewswire Inc.
BOSTON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sa
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
08:05pm, Thursday, 01'st Sep 2022 GlobeNewswire Inc.
BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-s
Paratek Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
08:00am, Thursday, 01'st Sep 2022
BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sav
Paratek Pharmaceuticals (PRTK) Q2 2022 Earnings Call Transcript
05:30am, Thursday, 04'th Aug 2022 The Motley Fool
PRTK earnings call for the period ending June 30, 2022.
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q2 2022 Results - Earnings Call Transcript
10:27pm, Wednesday, 03'rd Aug 2022
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Sarah Higgins - VP, Controller and Interim Principal Financial & Accounting
Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates
09:25pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Paratek (PRTK) delivered earnings and revenue surprises of 5.71% and 3.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates
06:48pm, Wednesday, 03'rd Aug 2022
Paratek (PRTK) delivered earnings and revenue surprises of 5.71% and 3.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
08:05pm, Monday, 01'st Aug 2022 GlobeNewswire Inc.
BOSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sa
Paratek Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022
08:05pm, Monday, 25'th Jul 2022 GlobeNewswire Inc.
BOSTON, July 25, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, Aug. 3 at 4:3
